No Data
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study
Aldeyra Therapeutics (ALDX) said Wednesday the first patient has been enrolled in a phase 3 dry eye chamber trial of reproxalap in dry eye disease. Reproxalap is an investigational reactive aldehyde s
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease, Clinical Results and Potential New Drug Application Submission Expected In 2H Of 2024
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease, Clinical Results and Potential New Drug
Express News | Aldeyra Therapeutics Inc - Clinical Results and Potential New Drug Application Submission Expected in Second Half of 2024
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced enrollment of the first patient in a Phase 3 dry eye chamber clinical trial designed to enable a potential resubmission of the New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease.
Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by Oppenheimer
Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by Oppenheimer